Coming Soon to Cryoport Systems: Cryoport Express® Cryogenic HV3 Advanced Therapy Shipper®
As the cell and gene therapy industry grows, quality requirements are continuously evolving and posing new challenges. In response, Cryoport Systems developed a new shipping system to support the demands of advanced therapy supply chains. Expected to launch in 2027, the HV3 Advanced Therapy Shipper (ATS) (CXHV3SPHU) will exclusively support clinical and commercial cell and gene therapy supply chains, with traceability, quality controls, and a scalable model for future expansion.
Building on HV3 to Expand the Reach of ATS
The HV3 ATS evolved out of the success of the Cryoport Express® Cryogenic HV3 Shipping System within our General Purpose (GP) fleet. The HV3 ATS is designed to move advanced therapies at every stage of the development lifecycle, while preserving integrity, traceability, and compliance. To do so, the shipping system will feature enhanced mobility and advanced design of the HV3 enclosure, paired with the rigorous controls of our ATS standards. These standards include strict physical and procedural segregation of the dewar, accessories, and supporting processes. By standardizing the HV3 enclosure while maintaining separate quality-driven controls for HV3 ATS and HV3 GP, Cryoport Systems established a scalable model for future product development that supports our clients’ evolving needs.
Reinforcing Safety and Quality Requirements
For additional safety assurance, the HV3 ATS will provide documentation that the dewar and its corresponding accessories have never been used to transport non-human cell and gene therapy materials. All shipments will also be supported by a Certificate of Conformance from a quality control inspection that verifies compliance with all applicable ATS requirements and includes distinct exterior ATS labels to ensure clear identification of the product type.
Cryoport Systems’ ATS fleet is intended to support cell and gene therapy supply chains. The fleet is equipped with dedicated human-use shipping systems, validated decontamination protocols, continuous condition monitoring, equipment qualification and requalification, documented equipment history, and end-to-end traceability through our Cryoportal®. These quality controls preserve product integrity and mitigate contamination risk across the shipment lifecycle while supporting compliance with ISO 21973 requirements for the transportation of cells for therapeutic use.
Launch and Implementation Plans
The HV3 ATS shipping system is expected to launch in 2027, with additional details available closer to the product being available for use. After our global launch, current HV2 ATS clients will have the opportunity to evaluate the operational performance benefits of the HV3 ATS model, as we continue elevating our support to meet clients’ complex programs.
Investing in the Evolving Cell and Gene Therapy Landscape
The advanced therapy ecosystem continues to demand new innovations and logistics solutions to support program success and scalability. Together, the HV3 ATS and our rigorous standards provide clients with greater confidence that valuable materials are securely transported using dedicated, qualified shipping systems designed to preserve product integrity, maintain traceability, and mitigate cross-contamination risks throughout the shipment lifecycle.
